|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the LLY 10-K filed Feb 22, 2010. Cymbalta
Boehringer
Ingelheim
We are in a collaborative arrangement with Boehringer Ingelheim
(BI) to jointly market and promote Cymbalta, a product for the
treatment of major depressive disorder, diabetic peripheral
neuropathic pain, generalized anxiety disorder, and
fibromyalgia, outside the U.S. Pursuant to the terms of the
agreement, we generally share equally in development, marketing,
and selling expenses, and pay BI a commission on
53
sales in the co-promotion territories. We manufacture the
product for all territories. Reimbursements or payments for the
cost sharing of marketing, selling, and administrative expenses
are recorded in the respective expense line items in the
consolidated statements of operations. The commission paid to BI
is recognized in marketing, selling, and administrative expenses.
Quintiles
We were in a collaborative arrangement with Quintiles
Transnational Corp. (Quintiles) to jointly market and promote
Cymbalta in the U.S. since Cymbalta’s launch in 2004.
Pursuant to the terms of the agreement, Quintiles shared in the
costs to co-promote Cymbalta with us and receives a commission
based upon net product sales. According to that agreement,
Quintiles’ obligation to promote Cymbalta expired during
2009, and we will pay a lower rate on net product sales for
three years after completion of the promotion efforts specified
in that agreement. The commissions paid to Quintiles are
recorded in marketing, selling, and administrative expenses.
|
| |||||||
